SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Oxford GlycoSciences Plc
An SI Board Since January 2000
Posts SubjectMarks Bans
469 13 0
Emcee:  Jongmans Type:  Unmoderated
Introduction Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
244J Biol Chem 2002 Nov 4; [epub ahead of print] Pneumocystis carinii cell wall bscaram(o)uche-11/8/2002
243OGS Announces the Start of a Phase I Clinical Study with OGT 923 Tuesday Novembescaram(o)uche-11/5/2002
242reminder, if anyone is interested..... OGS presents today at UBS Warburg. bescaram(o)uche-10/7/2002
241<i>looks like about seven quarters of burn, first blush</i> It'nigel bates-10/4/2002
240Unaudited Consolidated Profit and Loss Account <pre> nigel bates-10/4/2002
239OXFORD, England, Sept. 26 /PRNewswire-FirstCall/ -- Oxford GlycoSciences Plc (Nanigel bates-10/4/2002
238results thru 6/30 are out.... looks like about seven quarters of burn, first bscaram(o)uche-10/4/2002
237holmes and alibek need to get together...... Message 18026500 I hope that OGS scaram(o)uche-10/2/2002
236Scand J Immunol 2002 Sep;56(3):270-5 Sema7A is a potent monocyte stimulator. scaram(o)uche-10/2/2002
235One problem with this report - how do you go about negotiating merger/acquisitionigel bates-9/26/2002
234...EXTRACTS FROM CHAIRMAN AND CHIEF EXECUTIVE'S INTERIM STATEMENT INTRODUCTInigel bates-9/26/2002
233OXFORD, England, Sept. 23 /PRNewswire-FirstCall/ -- Oxford GlycoSciences Plc (LSnigel bates-9/23/2002
232Yes, but do you think it might get them to trade above cash ??nigel bates-9/19/2002
231That sounds very, very cool. Give the data to the FDA and if it becomes embeddekeokalani'nui-9/19/2002
230One way for them to get something out of the FDA ? OXFORD, England, Sept. 19 /Pnigel bates-9/19/2002
229CAMBRIDGE, Mass., Sept. 9 /PRNewswire-FirstCall/ -- Genzyme General (Nasdaq: GENnigel bates-9/9/2002
228Br J Cancer 2001 Apr 20;84(8):1107-14 N -butyldeoxynojirimycin reduces growth scaram(o)uche-7/26/2002
227J Neurosci 2002 Apr 1;22(7):2660-8 Metabotropic glutamate receptor 5 upregulatiscaram(o)uche-7/26/2002
226OGS Announces Positive CPMP Opinion for Zavesca(TM)* for Type 1 Gaucher Disease nigel bates-7/26/2002
225As you wish <g> - EU scientific committee backs OGS's Vevesca LONDONnigel bates-7/26/2002
224Now we're cookin'. More of these.keokalani'nui-7/12/2002
223OGS and Cystic Fibrosis Foundation Therapeutics Inc. Launch a Major Proteomics Inigel bates-7/12/2002
222At last look the company is set to burn L33m and it has said it plans to pursue keokalani'nui-6/25/2002
221<i>Time to stop this vevesca nonsense already.</i> I'll call thnigel bates-6/25/2002
220Time to stop this vevesca nonsense already.keokalani'nui-6/25/2002
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News